We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to a new move from the FDA, they might not have to wait that long.